BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

1442

500674

SANOFI

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SANOFI INDIA LIMITED performance

Today’s low

Today’s high

₹ 5901.00 ₹ 6049.00
₹ 5943.00

52 week low

52 week high

₹ 4902.00 ₹ 10524.95
₹ 5943.00

Open Price

₹ 6020.00

Prev. Close

₹ 6033.50

Volume (Shares)

25518.00

Total traded value

₹ 1516.53

Upper Circuit

₹ 7240.00

Lower Circuit

₹ 4827.00

info

SANOFI INDIA LIMITED Share Price Update

As of the latest trading session, SANOFI INDIA LIMITED share price is currently at ₹ 5943, which is down by ₹ -90.50 from its previous closing. Today, the stock has fluctuated between ₹ 5901.00 and ₹ 6049.00. Over the past year, SANOFI INDIA LIMITED has achieved a return of -28.61 %. In the last month alone, the return has been 1.68 %. Read More...

SANOFI INDIA LIMITED fundamentals


  • Market cap (Cr)

    13,686.70

  • P/E Ratio (TTM)

    33.04

  • Beta

    0.48

  • Book Value / share

    373.69

  • Return on equity

    47.15%

  • EPS (TTM)

    192.04

  • Dividend yield

    1.97%

  • Net profit/quarter (Cr)

    91.30

info icon alternate text
  • Market cap (Cr)

    13,662.20

  • P/E Ratio (TTM)

    33.04

  • Beta

    0.41

  • Book Value / share

    373.69

  • Return on equity

    47.15%

  • EPS (TTM)

    192.04

  • Dividend yield

    1.97%

  • Net profit/quarter (Cr)

    91.30

info icon alternate text

SANOFI INDIA LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 514.90
Operating Expense 406.59
Net Profit 91.30
Net Profit Margin (%) 17.73
Earnings Per Share (EPS) 39.64
EBITDA 132.20
Effective Tax Rate (%) 25.28
Particulars SEP 2024 (Values in Cr)
Revenue 524.00
Operating Expense 413.70
Net Profit 82.20
Net Profit Margin (%) 15.68
Earnings Per Share (EPS) 35.69
EBITDA 122.00
Effective Tax Rate (%) 26.99
Particulars JUN 2024 (Values in Cr)
Revenue 463.50
Operating Expense 357.20
Net Profit 103.40
Net Profit Margin (%) 22.30
Earnings Per Share (EPS) 44.90
EBITDA 101.50
Effective Tax Rate (%) 25.95
Particulars MAR 2024 (Values in Cr)
Revenue 510.80
Operating Expense 383.10
Net Profit 136.60
Net Profit Margin (%) 26.74
Earnings Per Share (EPS) 59.31
EBITDA 113.89
Effective Tax Rate (%) 31.10
Particulars DEC 2023 (Values in Cr)
Revenue 469.20
Operating Expense 379.29
Net Profit 137.70
Net Profit Margin (%) 29.34
Earnings Per Share (EPS) 59.89
EBITDA 109.00
Effective Tax Rate (%) 29.80
Particulars DEC 2024 (Values in Cr)
Revenue 2013.20
Operating Expense 1560.60
Net Profit 413.50
Net Profit Margin (%) 20.53
Earnings Per Share (EPS) 179.54
EBITDA 469.59
Effective Tax Rate (%) 27.28
Particulars DEC 2023 (Values in Cr)
Revenue 1996.10
Operating Expense 1546.60
Net Profit 603.20
Net Profit Margin (%) 30.21
Earnings Per Share (EPS) 261.91
EBITDA 566.70
Effective Tax Rate (%) 31.01
Particulars DEC 2022 (Values in Cr)
Revenue 2770.10
Operating Expense 2109.29
Net Profit 620.60
Net Profit Margin (%) 22.40
Earnings Per Share (EPS) 269.47
EBITDA 907.90
Effective Tax Rate (%) 28.19
Particulars DEC 2021 (Values in Cr)
Revenue 2956.60
Operating Expense 2262.60
Net Profit 944.40
Net Profit Margin (%) 31.94
Earnings Per Share (EPS) 410.06
EBITDA 1326.10
Effective Tax Rate (%) 24.90
Particulars DEC 2020 (Values in Cr)
Revenue 2901.90
Operating Expense 2272.80
Net Profit 477.60
Net Profit Margin (%) 16.45
Earnings Per Share (EPS) 207.38
EBITDA 761.20
Effective Tax Rate (%) 29.47
Particulars DEC 2024 (Values in Cr)
Book Value / Share 374.17
ROE % 47.13
ROCE % 47.95
Total Debt to Total Equity 0.02
EBITDA Margin 25.20
Particulars DEC 2023 (Values in Cr)
Book Value / Share 441.39
ROE % 58.01
ROCE % 48.12
Total Debt to Total Equity 0.02
EBITDA Margin 27.50
Particulars DEC 2004 (Values in Cr)
Book Value / Share 189.40
ROE % 40.83
ROCE % 59.81
Total Debt to Total Equity 0.05
EBITDA Margin 32.31
Particulars DEC 2003 (Values in Cr)
Book Value / Share 142.31
ROE % 31.91
ROCE % 45.43
Total Debt to Total Equity 0.05
EBITDA Margin 24.62
Particulars DEC 2024 (Values in Cr)
Book Value / Share 374.17
ROE % 47.15
ROCE % 47.94
Total Debt to Total Equity 0.02
EBITDA Margin 25.20
Particulars DEC 2023 (Values in Cr)
Book Value / Share 441.52
ROE % 51.43
ROCE % 42.70
Total Debt to Total Equity 0.02
EBITDA Margin 27.50
Particulars DEC 2022 (Values in Cr)
Book Value / Share 554.70
ROE % 30.05
ROCE % 40.25
Total Debt to Total Equity 0.01
EBITDA Margin 28.01
Particulars DEC 2021 (Values in Cr)
Book Value / Share 967.65
ROE % 26.75
ROCE % 33.80
Total Debt to Total Equity 0.01
EBITDA Margin 28.08
Particulars DEC 2020 (Values in Cr)
Book Value / Share 921.30
ROE % 20.94
ROCE % 28.88
Total Debt to Total Equity 0.00
EBITDA Margin 26.23
Particulars DEC 2024 (Values in Cr)
Cash & Short Term Investments 294.80
Total Assets 1611.80
Total Liabilities 1611.80
Total Equity 860.60
Share Outstanding 23030622
Price to Book Ratio 16.36
Return on Assets (%) 25.65
Return on Capital (%) 48.05
Particulars DEC 2023 (Values in Cr)
Cash & Short Term Investments 404.90
Total Assets 1715.10
Total Liabilities 1715.10
Total Equity 1015.50
Share Outstanding 23030622
Price to Book Ratio 18.27
Return on Assets (%) 35.16
Return on Capital (%) 59.4
Particulars DEC 2022 (Values in Cr)
Cash & Short Term Investments 1016.90
Total Assets 2071.70
Total Liabilities 2071.70
Total Equity 1275.80
Share Outstanding 23030622
Price to Book Ratio 10.55
Return on Assets (%) 29.95
Return on Capital (%) 48.64
Particulars DEC 2021 (Values in Cr)
Cash & Short Term Investments 1550.30
Total Assets 3061.00
Total Liabilities 3061.00
Total Equity 2225.60
Share Outstanding 23030622
Price to Book Ratio 8.16
Return on Assets (%) 30.85
Return on Capital (%) 42.43
Particulars DEC 2020 (Values in Cr)
Cash & Short Term Investments 1208.60
Total Assets 2918.50
Total Liabilities 2918.50
Total Equity 2119.00
Share Outstanding 23030622
Price to Book Ratio 9.03
Return on Assets (%) 16.36
Return on Capital (%) 22.54
Particulars DEC 2024 (Values in Cr)
Net Income 562.40
Cash from Operations 558.90
Cash from Investing -19.20
Cash from Financing -392.40
Net change in Cash 49.90
Free Cash Flow 595.30
Particulars DEC 2023 (Values in Cr)
Net Income 845.50
Cash from Operations 471.70
Cash from Investing 37.50
Cash from Financing -878.30
Net change in Cash -610.40
Free Cash Flow 506.00
Particulars DEC 2024 (Values in Cr)
Net Income 562.60
Cash from Operations 559.10
Cash from Investing -19.20
Cash from Financing -392.40
Net change in Cash 50.10
Free Cash Flow 595.50
Particulars DEC 2023 (Values in Cr)
Net Income 845.80
Cash from Operations 472.10
Cash from Investing 35.50
Cash from Financing -878.30
Net change in Cash -612.00
Free Cash Flow 506.40
Particulars DEC 2022 (Values in Cr)
Net Income 864.30
Cash from Operations 659.40
Cash from Investing 650.90
Cash from Financing -1582.70
Net change in Cash -533.10
Free Cash Flow 681.60
Particulars DEC 2021 (Values in Cr)
Net Income 1257.60
Cash from Operations 843.70
Cash from Investing 630.80
Cash from Financing -849.00
Net change in Cash 340.60
Free Cash Flow 866.70
Particulars DEC 2020 (Values in Cr)
Net Income 677.20
Cash from Operations 804.40
Cash from Investing 276.40
Cash from Financing -810.00
Net change in Cash 77.50
Free Cash Flow 845.80
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

SANOFI INDIA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
5943.00 -1.49 redarrow
red-green-graph indicator
12 Bearish
4 Bullish
  • 5 Days 6106.70
  • 26 Days 6040.90
  • 10 Days 6158.20
  • 50 Days 5898.70
  • 12 Days 6154.90
  • 100 Days 5936.80
  • 20 Days 6095.80
  • 200 Days 6256.50
6058.33 PIVOT

First Support

5995.17

First Resistance

6096.67

Second Support

5956.83

Second Resistance

6159.83

Third Support

5893.67

Third Resistance

6198.17

RSI

46.62

ADX

23.11

MACD

113.95

Williams % R

-94.85

Commodity Channel Index (CCI)

-58.73

Date

2025-04-30

Week

12789.00

Same Day

17478.00

Month

9133.00

1 Year

0.49

3 Year

0.31

Over 1 Month

1.68%

down

Over 1 Year

-28.61%

down

Over 3 Months

8.16%

down

Over 3 Years

-5.04%

down

Over 6 Months

-9.45%

down

Over 5 Years

-5.24%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

SANOFI INDIA LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
11.0%
Promoter Holdings
60.39%
FII
5.57%
DII
23.02%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Hoechst Gmbh 1.3904722E7 (60.37%) Shareholding of Promoter and Promoter Group
Life Insurance Corporation Of India - P & Gs Fund 1369833.0 (5.95%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund 893064.0 (3.88%) Public Shareholding
Sbi Magnum Midcap Fund 821051.0 (3.57%) Public Shareholding
Aditya Birla Sun Life Trustee Private Limited A/c Aditya Birla Sun Life Small Cap Fund 638073.0 (2.77%) Public Shareholding
General Insurance Corporation Of India 572689.0 (2.49%) Public Shareholding
Hdfc Life Insurance Companylimited -shareholders Solvency Margin Account 338763.0 (1.47%) Public Shareholding
Bajaj Allianz Life Insurance Company Ltd. 317556.0 (1.38%) Public Shareholding
Sanofi 4865.0 (0.02%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

SANOFI INDIA LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
07 Mar 2024 50.0 Interim 07 Mar 2024 Equity shares
28 Apr 2023 194.0 Final 29 Apr 2023 Equity shares
28 Apr 2023 183.0 Special 29 Apr 2023 Equity shares
05 Aug 2022 193.0 Special 08 Aug 2022 Equity shares
12 Apr 2022 181.0 Final 16 Apr 2022 Equity shares
12 Apr 2022 309.0 Special 16 Apr 2022 Equity shares
19 Apr 2021 125.0 Final 21 Apr 2021 Equity shares
19 Apr 2021 240.0 Special 21 Apr 2021 Equity shares
29 Jun 2020 106.0 Final 01 Jul 2020 Equity shares
29 Jun 2020 243.0 Special 01 Jul 2020 Equity shares
25 Apr 2019 66.0 Final 30 Apr 2019 Equity shares
06 Aug 2018 18.0 Interim 07 Aug 2018 Equity shares
26 Apr 2018 53.0 Final 01 May 2018 Equity shares
31 Jul 2017 18.0 Interim 01 Aug 2017 Equity shares
25 Apr 2017 50.0 Final 27 Apr 2017 Equity shares
04 Aug 2016 18.0 Interim 05 Aug 2016 Equity shares
13 Apr 2016 25.0 Final 19 Apr 2016 Equity shares
13 Apr 2016 14.0 Special 19 Apr 2016 Equity shares
13 Apr 2016 8.0 Special 19 Apr 2016 Equity shares
29 Jul 2015 18.0 Interim 30 Jul 2015 Equity shares
16 Apr 2015 24.0 Final 18 Apr 2015 Equity shares
16 Apr 2015 11.0 Special 18 Apr 2015 Equity shares
31 Jul 2014 10.0 Interim 01 Aug 2014 Equity shares
16 Apr 2014 35.0 Final 18 Apr 2014 Equity shares
05 Aug 2013 10.0 Interim 06 Aug 2013 Equity shares
05 Apr 2013 29.0 Final 09 Apr 2013 Equity shares
02 Aug 2012 4.0 Interim 03 Aug 2012 Equity shares
10 Apr 2012 29.0 Final 12 Apr 2012 Equity shares
03 Aug 2011 4.0 Interim 04 Aug 2011 Equity shares
31 Mar 2011 23.0 Final 06 Apr 2011 Equity shares
31 Mar 2011 28.0 Special 06 Apr 2011 Equity shares
26 Jul 2010 4.0 Interim 27 Jul 2010 Equity shares
07 Apr 2010 16.5 Final 09 Apr 2010 Equity shares
30 Jul 2009 3.5 Interim 31 Jul 2009 Equity shares
06 Apr 2009 12.5 Final 09 Apr 2009 Equity shares
29 Jul 2008 3.5 Interim 30 Jul 2008 Equity shares
03 Apr 2008 12.5 Final 05 Apr 2008 Equity shares
25 Jul 2007 3.5 Interim 26 Jul 2007 Equity shares
22 Mar 2007 12.5 Interim 2 24 Mar 2007 Equity shares
03 Aug 2006 3.5 Interim 04 Aug 2006 Equity shares
19 May 2006 0.0 Final 23 May 2006 Equity shares
03 Aug 2005 0.0 Interim 04 Aug 2005 Equity shares
07 May 2004 12.5 Final 12 May 2004 Equity shares
07 Aug 2003 3.5 Interim 08 Aug 2003 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
03 May 2024 117.0 Final 03 May 2024 Equity shares
07 Mar 2024 50.0 Interim 07 Mar 2024 Equity shares
28 Apr 2023 194.0 Final 29 Apr 2023 Equity shares
28 Apr 2023 183.0 Special 29 Apr 2023 Equity shares
05 Aug 2022 193.0 Special 08 Aug 2022 Equity shares
12 Apr 2022 181.0 Final 16 Apr 2022 Equity shares
12 Apr 2022 309.0 Special 16 Apr 2022 Equity shares
19 Apr 2021 125.0 Final 21 Apr 2021 Equity shares
19 Apr 2021 240.0 Special 21 Apr 2021 Equity shares
29 Jun 2020 106.0 Final 01 Jul 2020 Equity shares
29 Jun 2020 243.0 Special 01 Jul 2020 Equity shares
25 Apr 2019 66.0 Final 30 Apr 2019 Equity shares
06 Aug 2018 18.0 Interim 07 Aug 2018 Equity shares
26 Apr 2018 53.0 Final 01 May 2018 Equity shares
31 Jul 2017 18.0 Interim 01 Aug 2017 Equity shares
25 Apr 2017 50.0 Final 27 Apr 2017 Equity shares
04 Aug 2016 18.0 Interim 05 Aug 2016 Equity shares
13 Apr 2016 25.0 Final 19 Apr 2016 Equity shares
13 Apr 2016 14.0 Special 19 Apr 2016 Equity shares
13 Apr 2016 8.0 Special 19 Apr 2016 Equity shares
29 Jul 2015 18.0 Interim 30 Jul 2015 Equity shares
16 Apr 2015 24.0 Final 18 Apr 2015 Equity shares
16 Apr 2015 11.0 Special 18 Apr 2015 Equity shares
31 Jul 2014 10.0 Interim 01 Aug 2014 Equity shares
16 Apr 2014 35.0 Final 18 Apr 2014 Equity shares
05 Aug 2013 10.0 Interim 06 Aug 2013 Equity shares
05 Apr 2013 29.0 Final 09 Apr 2013 Equity shares
02 Aug 2012 4.0 Interim 03 Aug 2012 Equity shares
10 Apr 2012 29.0 Final 12 Apr 2012 Equity shares
03 Aug 2011 4.0 Interim 04 Aug 2011 Equity shares
31 Mar 2011 23.0 Final 06 Apr 2011 Equity shares
31 Mar 2011 28.0 Special 06 Apr 2011 Equity shares
26 Jul 2010 4.0 Interim 27 Jul 2010 Equity shares
07 Apr 2010 16.5 Final 09 Apr 2010 Equity shares
30 Jul 2009 3.5 Interim 31 Jul 2009 Equity shares
06 Apr 2009 12.5 Final 09 Apr 2009 Equity shares
29 Jul 2008 3.5 Interim 30 Jul 2008 Equity shares
03 Apr 2008 12.5 Final 05 Apr 2008 Equity shares
25 Jul 2007 3.5 Interim 26 Jul 2007 Equity shares
22 Mar 2007 12.5 Interim 2 24 Mar 2007 Equity shares
03 Aug 2006 3.5 Interim 04 Aug 2006 Equity shares
19 May 2006 0.0 Final 23 May 2006 Equity shares
03 Aug 2005 0.0 Interim 04 Aug 2005 Equity shares
07 May 2004 12.5 Final 12 May 2004 Equity shares
07 Aug 2003 3.5 Interim 08 Aug 2003 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

SANOFI INDIA LIMITED Share Price

Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012. The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals. It has its own manufacturing facility at Goa. It sells products through independent distributors primarily in India.

Sanofi India's products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India. The Company has its own manufacturing facility at Goa and Ankleshwar, Gujarat. It sells products through independent distributors primarily in India. Sanofi, one of the world's leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.37% of its paid-up share capital.

During the year 1997-98, the Joint Venture Company, Chiron Behring Vaccines Pvt Ltd started to manufacture anti-rabbies vaccine 'Rabipur'. Roussel India Ltd was amalgamated with the Company with effect from April 1, 1997 and Hoechst Nepal (Pvt) Ltd, a subsidiary Company in Nepal was wound up during the year. During the year 1999-2000, Aventis launched anti-diabetic Amaryl broad spectrum anti-infective Tavanic and line extension of anti-hypertensive Cardace H.

In the year 2001, Rhone-Poulenc Rorer (India) Pvt Ltd was amalgamated with the company. The company name was changed from Hoechst Marion Roussel Ltd to Aventis Pharma Ltd with effect from July 11 2001. In July 2003. the company launched Lantus, the world's first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched.

In the year 2004, the company came under the control of Sanofi-Synthelabo, now called sanofi-aventis which acquired indirect control 50.1% of the company's paid-up share capital. In the year 2006, the company completed the project for setting up additional facilities for manufacturing Combiflam Tablets in Ankleshwar, Gujarat.

In the year 2007, the company launched Cardace H 10 mg as a comprehensive cardiovascular treatment option in hypertension at risk patients. In May 2007, the company launched a line extension, Amaryl M. A new granulation train dedicated for production of Combiflam tablets was installed in Ankleshwar. This product which was being manufactured partly in a toll manufacturing site is now planned to be manufactured entirely in Ankleshwar.

In April 2008, the company launched a new prefilled diaposable insulin pen, SoloStar for use with the 24-hour insulin Lantus. This disposable insulin pen is to be used for the treatment of hyperglycemia in people with type 1 or type 2 diabetes.

On 13 December 2010, Aventis Pharma Ltd announced that it has agreed with its joint venture partner Novartis Vaccines & Diagnosics Inc. to sell its 49% shareholding in Chiron Behring Vaccines Private Limited (CBVPL) to Novartis Pharma AG and exit the joint venture. The purchase price agreed to be paid is US Dollars 22.399 million. Simultaneously, Aventis Pharma has agreed to continue to provide certain utilities and services to the Ankleshwar plant of CBVPL for a period of three years from the date of closing on mutually terms. CBVPL manufactures the anti-rabies vaccine Rabipur at its plant in Ankleshwar, which was until February 2009 distributed in India by Aventis Pharma and is presently distributed by Novartis Healthcare Private Limited.

On 27 December 2010, Aventis Pharma Ltd announced that it has completed the sale of its 49% shareholding in Chiron Behring Vaccines Private Limited to Novartis Pharma AG. The company received sale consideration of Rs 100.75 crore (equivalent to US Dollars 22.399 million).

On 24 August 2011, Aventis Pharma Limited (part of the Sanofi Group) announced that it has entered into a definitive agreement to acquire Universal Medicare Private Limited's business of marketing and distribution of branded nutraceutical formulations in India. Also, approximately 750 commercial employees will transition to Aventis Pharma Ltd. The transaction has been approved by the Boards of Directors of both companies. It is expected to close in the fourth quarter of 2011, subject to certain conditions precedent. Universal Medicare, (headquartered in Mumbai, India) manufactures, markets and distributes branded nutraceutical formulations in India through their sales and marketing infrastructure. With this acquisition, Aventis Pharma will advance its sustainable growth strategy in India and facilitate the creation of a consumer healthcare and wellness platform.

The Registrar of Companies approved the company's change of name from Aventis Pharma Limited to Sanofi India Limited with effect from 11 May 2012. The shareholders of the company had earlier approved the name change at the Annual General Meeting held on 3 May 2012. The decision to change the name of the Group's listed entity in India comes a year after the name of the parent company was changed globally from sanofi-aventis to Sanofi in May 2011.

On 9 October 2012, Sanofi India Limited announced the launch of AllStar, its first indigenously manufactured re-usable insulin pen.

On 14 February 2013, Sanofi India Limited announced the launch of Combiflam Plus, a targeted, fast and effective solution for headaches, which is also gentle on the stomach. A line extension of one of Sanofi India's flagship brand Combiflam, the launch of this new product marks the company's foray into the OTC headache segment in India.

On 11 November 2014, Sanofi India announced that its Board of Directors has approved of the company selling its commercial premises, being five floors and corresponding car-parking spaces in the building known as Hoechst House situated at Nariman Point, Mumbai to Bright Star Investments Private Limited and its Group companies for a total consideration of Rs 134.25 crore.

On 21 July 2015, Sanofi India announced that its Board of Directors has approved of the company selling its commercial property, being land and building at Andheri, Mumbai for a consideration of Rs 111 crore. The transaction is expected to be completed in the quarter ending 30 September 2015.

In August 2017, the first OTC extension of the iconic brand Combiflam was launched in the topical pain care space with the name Combiflam Icy Hot.

12 February 2018, Sanofi India announced the launch of its new insulin product Toujeo. Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.

In 2019, Sanofi launched Combiflam Plus (Paracetamol and Caffeine combination). Besides, two new brands were launched, DePura by Sanofi Cal.

During the year 2021-22, the Company's Nutraceuticals business, was sold as a going concern basis to Universal Nutriscience Private Limited through Slump Sale for a consideration of Rs. 587 Crore, effective on September 30, 2021. In 2021, a unique Toustarr pen, dedicated cartridge system device was launched.

In 2021, Company launched a unique Toustar pen, along with dedicated ToujeoTM cartridges, addressing the need for a reusable delivery device.

Through the Scheme of Arrangement among the Company and Sanofi Consumer Healthcare India Limited, the Consumer Healthcare Business of the Company got demerged into Company's wholly owned subsidiary, Sanofi Consumer Healthcare India Limited in 2022-23.

The Company launched multiple high-impact products in their respective categories: Frisium suspension (Neurology), Sanoxaban and Carmada (Cardiology) in 2023.

Parent organization MNC Associate - Hoechst
NSE symbol SANOFI
Founded 1956
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Sanofi India Ltd?

Answer Field

The share price of Sanofi India Ltd for NSE is ₹ 5943 and for BSE is ₹ 5915.

What is the Market Cap of Sanofi India Ltd?

Answer Field

The market cap of Sanofi India Ltd for NSE is ₹ 1,36,86.70 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Sanofi India Ltd?

Answer Field

The 52 Week High and Low of Sanofi India Ltd for NSE is ₹ 10524.95 and ₹ 4902.00 and for BSE is ₹ 10526.05 and ₹ 4145.90.

How to Buy Sanofi India Ltd share?

Answer Field

You can trade in Sanofi India Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Sanofi India Ltd?

Answer Field

The 1 year returns on the stock has been -28.61%.

What is the Current Share Price of Sanofi India Ltd?

Answer Field

Sanofi India Ltd share price is for NSE ₹ 5943 & for BSE ₹ 5915 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Sanofi India Ltd Share?

Answer Field

The market cap of Sanofi India Ltd for NSE ₹ 1,36,86.70 & for BSE ₹ 0.0 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Sanofi India Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Sanofi India Ltd share is 33.04.

What is the PB ratio of Sanofi India Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Sanofi India Ltd share is 373.69.

How to Buy Sanofi India Ltd Share?

Answer Field

You can trade in Sanofi India Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Sanofi India Ltd Share on Bajaj Broking App?

Answer Field

To buy Sanofi India Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Sanofi India Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|